Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real‐Life Setting

2020110 citationsJournal Articlebronze Open Access

Authors

Mariele Gatto · University of Padua

Francesca Saccon · University of Padua

Margherita Zen · University of Padua

Francesca Regola · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Micaela Fredi · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Laura Andréoli · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Anǵela Tincani

Abstract

In patients with active SLE and low damage at baseline, treatment with belimumab early in the disease may lead to favorable outcomes in a real-life setting.

Topics & Keywords

Systemic Lupus Erythematosus Research Monoclonal and Polyclonal Antibodies Research Atherosclerosis and Cardiovascular Diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Arthritis & Rheumatology

Volume 72, Issue 8, pp. 1314-1324

DOI: 10.1002/art.41253

Field-Weighted Citation Impact: 11.58